Celldex Therapeutics Inc (CLDX)
Quote as of 10:19 AM ET 07/29/2010 (NASDAQ GM)
| Last: 5.06 |
Change: ($0.03) |
Percent Change: -0.59 |
Volume: 36,821 |
Celldex Therapeutics, Inc. (Celldex) is a biopharmaceutical company, which applies its Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. The Company?s immunotherapy platform includes a portfolio of monoclonal antibodies, antibody-targeted vaccines, antibody-drug conjugates and immunomodulators to create disease-specific drug candidates. Its collaborations include the commercialization of an oral human rotavirus vaccine and the development of oncology and infectious disease vaccines. On October 1, 2009, Celldex acquired CuraGen Corporation.
Analyst Opinions
| |
Current |
1 Mo. |
3 Mo. |
| Strong Buy |
3.00 |
3.00 |
2.00 |
| Buy |
1.00 |
1.00 |
1.00 |
| Hold |
0.00 |
0.00 |
0.00 |
| Sell |
0.00 |
0.00 |
0.00 |
| Strong Sell |
0.00 |
0.00 |
0.00 |
|
|
Average Recommendation
| Current |
1.13 |
| 1 Mo. Ago |
1.13 |
| 3 Mo. Ago |
1.17 |
Recommendation Scale
| Strong Sell: 3.0 |
Hold: 2.0 |
Strong Buy: 1.0 |
|